Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 2 · 100%High 0 · 0%

Overall response rate · advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer

ALK inhibitor probably leads to higher overall response rate compared with any cytotoxic chemotherapy (moderate certainty).

1 finding from 1 review

Overall response rate · advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer

Next‐generation ALK inhibitor probably leads to higher overall response rate compared with crizotinib (moderate certainty).

1 finding from 1 review